The MiHAs have raised considerable interest as targets for selective immunotherapy after allo-HSCT because they are among the few MiHAs characterized at the molecular level that are expressed on hematopoietic tissues and some solid tumors, but not on healthy tissues of different origin. Therefore, MiHAs have potential value for therapeutic and diagnostic applications.
We combine the Single-Chain Minor Histocompatibility Complex Class I Molecules (SCMiHC) with the phage display technology. Here, the SCMiHC molecules were successfully incorporated at the tip of the filamentous bacteriophage fd as a fusion protein with its gene III product (g3p).
Single-Chain Minor Histocompatibility Complex Class I Molecules (SCMiHC) were corporated on the surface of the liposome, as an antigen-presenting vesicle. Meanwhile, we use other nanocarriers to built the multifunctional vesicle in a professional way.
Thanks to high accuracy bioinformatics algorithm and neural network models, the MiHA research were accelerate dramatically. Not only the high binding affinity motifs prediction became ture, but the structure-based immunogenicity prediction was realised. Especially the study of MiHA can at immunological synapse (IS) level after deep learning.